



BOB RILEY
Governor

Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624

www.medicaid.state.al.us
e-mail: almedicaid@medicaid.state.al.us
Telecommunication for the Deaf: 1-800-253-0799
1-800-362-1504 (334) 293-5500



CAROL A. HERRMANN-STECKEL, MPH
Commissioner

January 6, 2006

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on Wednesday, February 22, 2006. This meeting may involve review of one or more of your company's drug products. **Please note:** this meeting will be held at the Medicaid Executive Boardroom (Lurleen B. Wallace Building, 501 Dexter Avenue) located in Montgomery, AL and will begin at 9:00 a.m. All meetings of this committee are open to the public.

The following is a list of drug classes scheduled for review at this meeting:

DRUG CLASSES	
1. Antiarrhythmic Agents - AHFS 240404	7. HMG-COA Reductase Inhibitors – Single Entity AHFS 240608
2. Cardiotonic Agents - AHFS 240408	8. HMG-COA Reductase Inhibitors - Combination AHFS 240608
3. Nitrates and Nitrites – AHFS 241208	9. Miscellaneous Antilipemic Agents – AHFS 240692
4. Bile Acid Sequestrants – AHFS 240604	10. Platelet Aggregation Inhibitors
5. Cholesterol Absorption Inhibitors – AHFS 240605	
6. Fibric Acid Derivatives – AHFS 240606	

As you may be aware, manufacturers whose products are scheduled for review are allowed the opportunity to provide written clinical comments for distribution to the Medicaid P&T Committee members prior to the meeting. All written comments must be received by Medicaid's Clinical Contractor, *MedMetrics Health Partners (re: AL Medicaid P&T Support; 100 Century Drive; Worcester, MA 01606)*, no later than **Wednesday, February 1, 2006**.

Please note: Written comments should be limited to clinical information only and **should not contain any reference to cost**. Manufacturers must provide 20 copies of written comments upon submission to *MedMetrics*. Failure to abide by all of these requirements upon submission will result in a rejection of the clinical comments in their entirety.

For products slated for P&T review, manufacturers are also allowed the opportunity to make brief (no more than 5 minutes) oral summary presentations of product clinical data to the Medicaid P&T Committee on the day of the meeting. Written notification of your intent to make an oral presentation at this meeting, as well as a one-page (single-sided) summary of the material to be presented must also be received by *MedMetrics Health Partners* no later than **Wednesday, February 1, 2006**. Oral presentations must also be limited to clinical (**non-cost-related**) information only.

Please refer to the Medicaid web-site for additional information related to presentations, timelines, clinical comment submissions, and/or submission of volume discounts. If you should have additional questions regarding this notice or if you have received this letter and are no longer the appropriate contact please contact the Medicaid Pharmacy Program at (334) 242-5050.

Sincerely,

Bakeba R. Thomas
Administrator, Pharmacy Clinical Services